Kevin Zen

Title: Kevin Zen: Innovator in Biotherapeutics

Introduction

Kevin Zen is a prominent inventor based in Del Mar, CA (US). He has made significant contributions to the field of biotherapeutics, particularly in the development of fusion proteins that target angiogenesis. With a total of 3 patents to his name, Zen's work is paving the way for innovative treatments in various clinical conditions.

Latest Patents

One of Kevin Zen's latest patents is focused on fusion proteins for inhibiting angiogenesis. This invention relates to biologics that inhibit the integrin activated pathway and another angiogenic factor-activated pathway. The patent details the compositions of these fusion proteins, as well as methods for producing and utilizing them. Another notable patent describes a fusion protein comprising a ligand binding domain of VEGF and PDGF. This invention includes fusion proteins that contain a PDGF binding portion, a VEGF binding portion, and an Fc antibody region. The patent also covers nucleic acids encoding these fusion proteins, their compositions, and methods for using them to treat or prevent conditions characterized by abnormal angiogenesis, such as vascular permeability, edema, or inflammation.

Career Highlights

Throughout his career, Kevin Zen has worked with several companies, including Allgenesis Biotherapeutics Inc. and Ap Biosciences Inc. His experience in these organizations has contributed to his expertise in the field of biotherapeutics and innovation.

Collaborations

Kevin has collaborated with notable coworkers such as Pei-Tzu Wu and Jia-Hau Shiu. These partnerships have likely enhanced his research and development efforts in creating effective biotherapeutic solutions.

Conclusion

Kevin Zen is a distinguished inventor whose work in fusion proteins is making a significant impact in the field of biotherapeutics. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.